Targacept Inc. (TRGT) announced top-line results from two separate exploratory Phase 2 studies of its product candidate TC-6987 conducted in the U.S., one in asthma and one in type 2 diabetes.
In the asthma study, oral TC-6987 met protocol-defined success criteria on both co-primary outcome measures, change from baseline in forced expiratory volume for adjunct TC-6987 compared to adjunct placebo measured at two time points on day 28. In the type 2 diabetes study, the primary outcome measure, change in fasting plasma glucose, was not met, and Targacept would not pursue further development of TC-6987 as a treatment for diabetes.
TC-6987 is a modulator of the alpha7 neuronal nicotinic receptor discovered by Targacept scientists using Pentad, the company's proprietary drug discovery platform.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.